Synergy of triazolyl substituents at C1 and C3 of galactose for high-affinity and selective galectin-4C inhibition

Alexander Dahlqvist; Rob Marc Go; Chandan Kishor; Hakon Leffler; Helen Blanchard; Ulf J. Nilsson

doi:10.1039/d5cb00106d

January 1, 2025RSC Chemical BiologyOpen Access

Synergy of triazolyl substituents at C1 and C3 of galactose for high-affinity and selective galectin-4C inhibition

View Full Paper

Ask AI

Bookmark

Share

Key Points

High-affinity inhibition of galectin-4 was achieved using triazolyl substituents, enhancing selectivity and efficacy.
The study highlights the unique binding specificity of galectin-4 compared to other galectins, enabling targeted therapeutic approaches.
Inhibitors developed demonstrate potential in addressing conditions like cancer progression and ulcerative colitis with selective action.
Further investigation into the mechanisms of action is warranted, given galectin-4's role in various pathophysiological processes.

Implication

Research reveals high-affinity selective inhibitors of galectin-4 in cancer and fibrosis, suggesting broader therapeutic applications.

Abstract

Galectin-4 differs from other galectins in carbohydrate-binding specificity, cellular and pathophysiological function, and roles in e.g . cancer progression, fibrosis, and ulcerative colitis, making potent, selective inhibitors desired.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dahlqvist et al. (2025) studied this question.

synapsesocial.com/papers/68c1a3f954b1d3bfb60de220 https://doi.org/10.1039/d5cb00106d

View Full Paper

Ask AI

Bookmark

Share

Synergy of triazolyl substituents at C1 and C3 of galactose for high-affinity and selective galectin-4C inhibition

Key Points

Implication

Abstract

Discussion

Cite This Study

Synergy of triazolyl substituents at C1 and C3 of galactose for high-affinity and selective galectin-4C inhibition

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading